|
Vyne Therapeutics Inc (NASDAQ: VYNE) |
|
Vyne Therapeutics Inc
VYNE's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Looking into Vyne Therapeutics Inc growth rates, revenue grew
by 6.14 % in III. Quarter 2024 from the same quarter a year ago.
Ranking at No. 2497
Major Pharmaceutical Preparations industry recorded
growth of revenues by 9.75 %
Vyne Therapeutics Inc net loss increased from $-7 millions, to $-12 millions in III. Quarter 2024,
• More on VYNE's Growth
|
|
Vyne Therapeutics Inc realized a net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 128.17 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 212.4.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.44.
• More on VYNE's Valuation
|
|
|
|
|
Vyne Therapeutics Inc realized net loss in trailing twelve months.
Company is currently trading with Price to Cash flow multiple of 128.17 in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Company's Price to Sales ratio is at 212.4.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.44.
Vyne Therapeutics Inc Price to Book Ratio is at 1.65 lower than Industry Avg. of 84.23. and higher than S&P 500 Avg. of 0.01
• More on VYNE's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com